Drug intelligence / Profile preview

atezolizumab + pertuzumab + trastuzumab

Development stage: Unknown
Lead developer: Roche
Modality: Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

A combination therapy consisting of atezolizumab (a PD-L1 inhibitor), pertuzumab (a HER2 dimerization inhibitor), and trastuzumab (a HER2-targeted monoclonal antibody). This regimen combines immune checkpoint inhibition with dual HER2 blockade, targeting both the immune system and HER2-driven signaling pathways in cancer cells.

Targets

HER2 ECD II (Human epidermal growth factor receptor 2 domain II)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on atezolizumab + pertuzumab + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atezolizumab + pertuzumab + trastuzumab.

Explore the full profile